Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00506935 · ClinicalTrials.gov registry record · Phase 1
Assessment of GVG for the Treatment of Methamphetamine Dependence
A Phase 1 study of Methamphetamine Addiction, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT00506935: Completed Phase 1 study of Methamphetamine Addiction, sponsored by Baylor College of Medicine.
NCT00506935 is a Phase 1 study of Methamphetamine Addiction that has completed, run by Baylor College of Medicine. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00506935, a Phase 1 study of Methamphetamine Addiction, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if GVG can reduce drug use and determine safety and effects of GVG when used together with methamphetamine. This study involves staying in the hospital for 21 days. Participants will receive either placebo or GVG, and a limited amount if methamphetamine will be injected on some study days. This study will enroll people that use methamphetamine. Participants will be compensated.
Conditions Studied
Interventions
- DRUG placebo
- DRUG GVG
Study Locations (1)
California
- UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
What the finished NCT00506935 record still lists
NCT00506935 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Methamphetamine Addiction appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00506935 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00506935 about?
NCT00506935 is a clinical study titled "Assessment of GVG for the Treatment of Methamphetamine Dependence". The purpose of this study is to find out if GVG can reduce drug use and determine safety and effects of GVG when used together with methamphetamine. This study involves staying in the hospital for 21 days. Participants will receive either placebo or GVG, and a limited amount if methamphetamine will ...
What is the current status of trial NCT00506935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2006-07. Estimated completion is 2008-06.
What conditions does trial NCT00506935 study?
This clinical trial studies the following conditions: Methamphetamine Addiction.
What interventions are being tested in trial NCT00506935?
The interventions under investigation include: placebo (DRUG), GVG (DRUG).
Who is sponsoring clinical trial NCT00506935?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00506935 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00506935's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia